|
|
 Previous Article | Table of Contents | Next Article 
Phenotypic difference of normal plasma cells from mature myeloma cells
H Harada, MM Kawano, N Huang, Y Harada, K Iwato, O Tanabe, H Tanaka, A Sakai, H Asaoku and A Kuramoto
Department of Internal Medicine, Hiroshima University, Japan.
We have recently shown that two-color analysis with fluorescein
isothiocyanate (FITC)-anti-CD38 antibody could clearly distinguish myeloma
cells (plasma cells) from other hematopoietic cells in the bone marrow.
Myeloma cells (plasma cells) alone were located at CD38strong positive (++)
fractions. To further distinguish normal plasma cells from mature myeloma
cells phenotypically, we examined immunophenotypes of normal plasma cells
and myeloma cells by two-color flow cytometry with FITC-anti-CD38 antibody
and phycoerythrin staining with antibody to VLA-4, MPC-1, CD44, CD56, CD19,
CD20, CD24, or CD10. Normal plasma cells were all VLA-4+VLA-5+MPC-1+CD44+
CD19+CD56- in the bone marrows from seven healthy donors, tonsils from four
patients with chronic tonsillitis, a spleen from one patient with
idiopathic thrombocytopenic purpura, and lymph nodes from two patients with
chronic lymphadenitis, respectively. On the other hand, mature myeloma
cells (12 of 20 cases), VLA-4+VLA-5+MPC-1+, were all CD19- and most of them
CD56+, and there were no myeloma cells with the CD19+CD56- phenotype in the
20 cases of myelomas we tested. Thus, as for the expression of CD19 and
CD56, normal plasma cells from various tissues are all CD19+CD56-, whereas
no myeloma cells have the CD19+CD56- phenotype. According to this finding,
we investigated the expression of CD19 and CD56 on plasma cells (CD38++
fractions) in monoclonal gammopathy of undetermined significance (MGUS).
Both CD19+CD56- and CD19-DC56+ plasma cells were found in all five cases of
MGUS we tested, suggesting that MGUS consists of phenotypically normal
plasma cells and myeloma cells. Therefore, it is reasoned that phenotypic
analysis of plasma cells with anti-CD19 and anti-CD56 antibodies can
distinguish normal plasma cells from malignant plasma cells (myeloma
cells), and can detect malignant plasma cells even in MGUS or premyeloma
states.
Volume 81,
Issue 10,
pp. 2658-2663,
05/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Weller, M. Mamani-Matsuda, C. Picard, C. Cordier, D. Lecoeuche, F. Gauthier, J.-C. Weill, and C.-A. Reynaud
Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+IgD+CD27+ B cell repertoire in infants
J. Exp. Med.,
June 9, 2008;
205(6):
1331 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al.
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Haematologica,
March 1, 2008;
93(3):
431 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. Pun Lee, C.-W. V. Lee, et al.
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
Blood,
December 1, 2007;
110(12):
3959 - 3967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Perez-Persona, M.-B. Vidriales, G. Mateo, R. Garcia-Sanz, M.-V. Mateos, A. G. de Coca, J. Galende, G. Martin-Nunez, J. M. Alonso, N. de las Heras, et al.
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Blood,
October 1, 2007;
110(7):
2586 - 2592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Airoldi, E. Di Carlo, C. Cocco, C. Sorrentino, F. Fais, M. Cilli, T. D'Antuono, M. P. Colombo, and V. Pistoia
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy
Blood,
December 1, 2005;
106(12):
3846 - 3853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease
PNAS,
October 18, 2005;
102(42):
15178 - 15183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cepok, B. Rosche, V. Grummel, F. Vogel, D. Zhou, J. Sayn, N. Sommer, H.-P. Hartung, and B. Hemmer
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
Brain,
July 1, 2005;
128(7):
1667 - 1676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mateo, M. Castellanos, A. Rasillo, N. C. Gutierrez, Ma. A. Montalban, Ma. L. Martin, J. Ma. Hernandez, Ma. C. Lopez-Berges, L. Montejano, J. Blade, et al.
Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma
Clin. Cancer Res.,
May 15, 2005;
11(10):
3661 - 3667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liu, H. Ishikawa, F.-J. Li, Z. Ma, K.-i. Otsuyama, H. Asaoku, S. Abroun, X. Zheng, N. Tsuyama, M. Obata, et al.
Dehydroepiandrosterone Can Inhibit the Proliferation of Myeloma Cells and the Interleukin-6 Production of Bone Marrow Mononuclear Cells from Patients with Myeloma
Cancer Res.,
March 15, 2005;
65(6):
2269 - 2276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kouno, T. Watanabe, T. Umeda, Y. Beppu, R. Kojima, K. Sungwon, Y. Kobayashi, K. Tobinai, T. Hasegawa, and Y. Matsuno
CD56-positive Small Round Cell Tumor: Osseous Plasmacytoma Manifested in Osteolytic Tumors of the Iliac Bone and Femora
Jpn. J. Clin. Oncol.,
February 1, 2005;
35(2):
90 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson, et al.
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells
Cancer Res.,
July 1, 2004;
64(13):
4629 - 4636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Arce, E. Luger, G. Muehlinghaus, G. Cassese, A. Hauser, A. Horst, K. Lehnert, M. Odendahl, D. Honemann, K.-D. Heller, et al.
CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations
J. Leukoc. Biol.,
June 1, 2004;
75(6):
1022 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O'Nions and M. J. Allday
Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogens
J. Gen. Virol.,
April 1, 2004;
85(4):
881 - 895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Robillard, H. Avet-Loiseau, R. Garand, P. Moreau, D. Pineau, M.-J. Rapp, J.-L. Harousseau, and R. Bataille
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
Blood,
August 1, 2003;
102(3):
1070 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, F. E. Davies, R. DasGupta, A. J. Ashcroft, R. Patmore, M. T. Drayson, R. G. Owen, A. S. Jack, J. A. Child, and G. J. Morgan
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
Blood,
October 16, 2002;
100(9):
3095 - 3100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, M. R. Yuille, J. Fuller, M. Cullen, B. Kennedy, S. J. Richards, A. S. Jack, E. Matutes, D. Catovsky, P. Hillmen, et al.
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
Blood,
September 18, 2002;
100(7):
2289 - 2290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, M. J. Green, A. Kuzmicki, B. Kennedy, J. A. L. Fenton, P. A. S. Evans, S. J. M. O'Connor, S. J. Richards, G. J. Morgan, A. S. Jack, et al.
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts
Blood,
June 28, 2002;
100(2):
635 - 639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Ely and D. M. Knowles
Expression of CD56/Neural Cell Adhesion Molecule Correlates with the Presence of Lytic Bone Lesions in Multiple Myeloma and Distinguishes Myeloma from Monoclonal Gammopathy of Undetermined Significance and Lymphomas with Plasmacytoid Differentiation
Am. J. Pathol.,
April 1, 2002;
160(4):
1293 - 1299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Medina, C. Segundo, A. Campos-Caro, I. Gonzalez-Garcia, and J. A. Brieva
The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression
Blood,
March 15, 2002;
99(6):
2154 - 2161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. San Miguel, J. Almeida, G. Mateo, J. Blade, C. Lopez-Berges, D. Caballero, J. Hernandez, M. J. Moro, J. Fernandez-Calvo, J. Diaz-Mediavilla, et al.
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
Blood,
March 1, 2002;
99(5):
1853 - 1856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Hargreaves, P. L. Hyman, T. T. Lu, V. N. Ngo, A. Bidgol, G. Suzuki, Y.-R. Zou, D. R. Littman, and J. G. Cyster
A Coordinated Change in Chemokine Responsiveness Guides Plasma Cell Movements
J. Exp. Med.,
July 2, 2001;
194(1):
45 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Rasmussen, L. Jensen, L. Honore, and H. E. Johnsen
Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma
Blood,
December 15, 2000;
96(13):
4357 - 4359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, J. A. L. Fenton, J. Ashcroft, A. English, R. A. Jones, S. J. Richards, G. Pratt, R. Owen, F. E. Davies, J. A. Child, et al.
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
Blood,
December 1, 2000;
96(12):
3880 - 3886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Mahmoud, R. Fujii, H. Ishikawa, and M. M. Kawano
Enforced CD19 Expression Leads to Growth Inhibition and Reduced Tumorigenicity
Blood,
November 15, 1999;
94(10):
3551 - 3558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Guise and G. R. Mundy
Cancer and Bone
Endocr. Rev.,
February 1, 1998;
19(1):
18 - 54.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Yi, S. Dabadghao, A. Osterborg, S. Bergenbrant, and G. Holm
Myeloma Bone Marrow Plasma Cells: Evidence for Their Capacity as Antigen-Presenting Cells
Blood,
September 1, 1997;
90(5):
1960 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bataille and J.-L. Harousseau
Multiple Myeloma
N. Engl. J. Med.,
June 5, 1997;
336(23):
1657 - 1664.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Arpin, J Dechanet, C Van Kooten, P Merville, G Grouard, F Briere, J Banchereau, and Y. Liu
Generation of memory B cells and plasma cells in vitro
Science,
May 5, 1995;
268(5211):
720 - 722.
[Abstract]
[PDF]
|
|
|
|
|
